Premium
A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
Author(s) -
O'Kane MJ,
Trinick TR,
Tynan MB,
Trimble ER,
Nicholls DP
Publication year - 1992
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1992.tb04067.x
Subject(s) - nicotinic agonist , triglyceride , placebo , medicine , endocrinology , niacin , chemistry , cholesterol , receptor , alternative medicine , pathology
The side effect profiles and lipid lowering efficacy of nicotinic acid (1 g three times daily) and its analogue acipimox (250 mg three times daily) in type 2b hyperlipidaemia were compared in a double‐blind placebo controlled study. In the nicotinic acid group (n = 7) at 12 weeks there were significant reductions (P less than 0.05) with respect to placebo (n = 9) in total cholesterol (median and range) 6.6 mmol l‐1 (4.8‐8.4) vs 8.8 mmol l‐1 (7.5‐9.5), triglyceride 1.4 mmol l‐1 (0.5‐ 4.6) vs 2.8 mmol l‐1 (1.5‐9.5) and apoprotein B 88.6 mg dl‐1 (62.1‐114) vs 121.9 mg dl‐1 (88.0‐170.7). In contrast there was no significant alteration in lipids in the acipimox group (n = 12). Nicotinic acid was associated with a high incidence of side effects, principally cutaneous flushing, while acipimox was well tolerated by all patients.